Sanofi VITALIZE A Phase 3, randomized, double-blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy. The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will […]
BMS TARGET-TAU This study is being done to learn more about the safety and efficacy of an investigational medication called BMS-986446 in adults aged 50-80 years with mild cognitive impairment due to Alzheimer’s disease, or mild Alzheimer’s dementia. Inclusion Criteria: Are 50-80 years old Have a diagnosis of mild cognitive impairment due to Alzheimer’s disease,
TG ENABLE The purpose of this study is to evaluate safety, effectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting. Inclusion Criteria: Participants with a confirmed Multiple Sclerosis (MS) diagnosis who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion. For more
EVIDERA EVA-38569-03 This is a cognitive interview study to evaluate Phase 2 Trial Anchors in Patients with Parkinson’s Disease. What to Expect This study involves in-depth interviews with adults who have been diagnosed with PD who meet specific criteria. For more information, contact Heather Macnamara at hmacnamara@dentinstitute.com or 716-819-4117
EVIDERA EVA-38569-03 Read More »
TEVA IMPACT TD Registry (Tardive Dyskinesia) The purpose of this study is to uncover how tardive dyskinesia (TD) develops over time and its impact on individuals. Inclusion Criteria: Patients who are newly initiating deutetrabenazine as part of routine clinical practice. What to Expect As part of your usual care, you will complete questionnaires and visit
Alzheimer’s National Registry for Treatment and Diagnostics(ALZ-NET) (Mild Cognitive Impairment and Alzheimer’s Disease) ALZ-NET collects clinical and safety data about patients being evaluated for memory concerns or receiving new FDA-approved treatments for Alzheimer’s disease, including drugs/medications and devices, and tracks the long-term health outcomes associated with their use in real-world settings. ALZ-NET is a voluntary
Migraine prevention injection in patients with unsuccessful prior preventive treatments The objective of the trial is to assess the efficacy of the study drug for prevention of migraine at different doses compared to placebo in patients who have failed multiple preventive treatments. Inclusion Criteria: In order to be eligible, you have to have at least
Migraine prevention injection in patients with unsuccessful prior preventive treatments Read More »
Chronic Migraine Implant for Migraine Prevention (RELIEV-CM2) The purpose of the RELIEV-CM2 study is to evaluate ShiraTronics Migraine Therapy System’s ability to reduce the frequency of headaches for those living with chronic migraine. Inclusion Criteria: You may be eligible for this study if your doctor has diagnosed you with chronic migraine and you meet the
Chronic Migraine Implant for Migraine Prevention (RELIEV-CM2) Read More »
Menstrual Migraine Prevention using Ubrelvy This study will evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension Inclusion Criteria: In order to be eligible for this study, you must be at least 18 years old and have a diagnosis of Menstrual Migraine What to Expect
Menstrual Migraine Prevention Read More »
JAZZ PATAGONIA (Parkinson’s Disease) This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson’s disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD
